" class="no-js "lang="en-US"> Fujitsu launches Cloud-based Platform for Healthcare in Japan
Monday, April 22, 2024

Fujitsu launches Cloud-based Platform for Healthcare in Japan

Fujitsu today announced the launch of a new cloud-based platform that allows users to securely collect and leverage health-related data to promote digital transformation in the medical field in Japan. The new offering represents part of Fujitsu’s ongoing efforts to contribute to the creation of a healthy society as part of its vision for “Healthy Living” under Fujitsu Uvance to create a sustainable world. Fujitsu will offer the new platform to medical institutions and pharmaceutical companies in Japan starting March 28, 2023.

The new platform enables the automatic conversion of medical data from medical institutions’ electronic medical records to conform with the next-generation standards framework HL7 FHIR and secure aggregation of health-related data. Based on their consent, patients can securely store personal health information such as vital data, step counts, and calorie consumption – converted into non-personally identifiable information on the platform – this in turn supports medical institutions and pharmaceutical companies in performing data analysis and R&D activities to accelerate the development of individualized healthcare and the discovery of new drugs.

Fujitsu will use the platform as a launching point for further planning to develop a data portability service that enables patients to view their medical data on their smartphones, as well as a service for medical institutions to conduct highly accurate analysis of shared medical data on the platform.

Moving forward, Fujitsu aims to leverage this platform to realize an AI and IoT based preventive healthcare system, and cooperate with various medical institutions and companies to realize a digital health ecosystem that creates new value for society.

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more